Publications

Activity of the novel Fabl inhibitor Debio 1452 against intracellular forms of susceptible and resistant S. aureus: comparison with linezolid,…

Efficacy and Safety Of AFN-1252, The First Staphylococcus-Specific Antibacterial Agent, in The Treatment of Acute Bacterial Skin And Skin Structure…

Clinical Safety, Pharmacokinetics and Early Evidence of Activity of The Oral IAPs Inhibitor Debio 1143 in Combination with Carboplatin and…

SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells

The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNF-alpha-mediated in head and neck squamous cell carcinoma.

Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a FabI Inhibitor, the Prodrug Debio 1450 and…

Safety, tolerability and pharmacokinetics of AFN–1252 administered as immediate release tablets in healthy subjects

Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute…

Phase I Dose-escalation Study with Extended Daily Administration of Debio 1143, an Oral Inhibitor of Apoptosis Protein Inhibitor, in Patients…